The rarity of sarcoma complicates clinical trial design and biomarker-driven treatment, explains Alexander Spira, MD, PhD, ...
In today's ACT Brief, we examine quantified reductions in trial visits through selective safety data collection, why protocol ...
Protocol design does not struggle in the protocol. It struggles in the transition to trial, when assumptions embedded in the ...
How AI Is Transforming Trial Design Artificial intelligence has become an integral part of the vision for clinical research ...
The US Food and Drug Administration (FDA) has revised a 2023 draft guidance on master protocols for drug and biological ...
Furthermore, increasing complexity in cancer clinical trial design has led to challenges such as protocol deviations, slow enrollment leading to lengthened durations of trial, and escalating costs. By ...
Health care is undergoing an important and well-needed shift from a one-size-fits-all approach to more personalized, precise, patient-focused care. A similar approach needs to be implemented at scale ...
Design Therapeutics, Inc. announced the initiation of a Phase 1 clinical trial for its gene-targeted treatment DT-216P2 in healthy volunteers, with patient dosing for Friedreich Ataxia (FA) set to ...
These therapeutic categories have not only been making headlines in 2026; they are fundamentally reshaping both clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results